BioCrude Technologies USA, Inc. financial data

Industry
Refuse Systems
Location
1255 Phillips Square, Suite 605, Montreal, Quebec, Canada
State of incorporation
NV
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.06 %
Debt-to-equity -114 % -1.96%
Return On Equity 119 % -19.1%
Return On Assets -954 % +33.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.9M shares +0.1%
Common Stock, Shares, Outstanding 50.9M shares +0.12%
Entity Public Float 0 USD
Common Stock, Value, Issued 50.9K USD +0.12%
Weighted Average Number of Shares Outstanding, Basic 50.8M shares +0.07%
Weighted Average Number of Shares Outstanding, Diluted 50.8M shares +0.07%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
General and Administrative Expense 271K USD +2.31%
Operating Income (Loss) -271K USD -2.31%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -275K USD -2.24%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 35.5K USD +24519%
Property, Plant and Equipment, Net 14.9K USD -5.84%
Assets 50.4K USD +215%
Liabilities, Current 277K USD +30%
Liabilities 277K USD +30%
Accumulated Other Comprehensive Income (Loss), Net of Tax 28.7K USD -0.11%
Retained Earnings (Accumulated Deficit) -9.39M USD -3.01%
Stockholders' Equity Attributable to Parent -223K USD -15%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -226K USD -15%
Liabilities and Equity 50.4K USD +215%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -79.4K USD -428%
Net Cash Provided by (Used in) Financing Activities 79.5K USD +430%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 50.9M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -26K USD -1550%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 257 USD +78.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 418K USD +13.9%
Depreciation 1.09K USD +6.9%
Payments to Acquire Property, Plant, and Equipment 0 USD
Property, Plant and Equipment, Gross 36.1K USD +10.7%
Additional Paid in Capital 9.08M USD +2.78%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 3.67K USD -2.76%